|
US6417165B1
(en)
|
1988-03-27 |
2002-07-09 |
Ludwig Institute For Cancer Research |
NY-ESO-1-peptide derivatives, and uses thereof
|
|
US6723832B1
(en)
*
|
1996-10-03 |
2004-04-20 |
Ludwig Institute For Cancer Research |
Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
|
|
US6252052B1
(en)
*
|
1996-10-03 |
2001-06-26 |
Cornell Research Foundation, Inc |
Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
|
|
US6255470B1
(en)
*
|
1996-10-03 |
2001-07-03 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
|
|
US7888100B2
(en)
*
|
1996-10-03 |
2011-02-15 |
Memorial Sloan-Kettering Cancer Research |
Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
|
|
US6251603B1
(en)
*
|
1996-10-03 |
2001-06-26 |
Ludwig Institute For Cancer Research |
Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
|
|
US6794131B1
(en)
*
|
1998-01-27 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Lage-1 tumor associated nucleic acids
|
|
ZA98656B
(en)
|
1997-01-27 |
1998-08-17 |
Ludwig Inst Cancer Res |
Lage-1 tumer associated nucleic acids
|
|
US6287756B1
(en)
*
|
1997-05-05 |
2001-09-11 |
Ludwig Institute For Cancer Research |
Methods for determining presence of cancer in a sample by determining expression of an SSX gene
|
|
US6673350B2
(en)
*
|
1997-05-05 |
2004-01-06 |
Ludwig Institute For Cancer Research |
Tumor associated peptide and uses thereof
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
DE69837273T2
(de)
*
|
1997-10-08 |
2008-01-31 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
|
|
US7084239B1
(en)
|
1997-10-08 |
2006-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cancer peptides of NY-ESO-1/CAG-3
|
|
EP1806403A3
(en)
*
|
1997-10-08 |
2008-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
|
|
US7001999B1
(en)
*
|
1998-04-15 |
2006-02-21 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
|
US6140050A
(en)
*
|
1998-06-26 |
2000-10-31 |
Ludwig Institute For Cancer Research |
Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
|
|
US6800730B1
(en)
*
|
1998-10-02 |
2004-10-05 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to MHC class II molecules, and uses thereof
|
|
WO2000050595A2
(en)
*
|
1999-02-25 |
2000-08-31 |
Ivan Gout |
Nucleic acid molecules associated with melanoma and thyroid tumors
|
|
DE19949595A1
(de)
*
|
1999-10-14 |
2001-05-03 |
Deutsches Krebsforsch |
CTAGE-Genfamilie
|
|
CA2388301C
(en)
|
1999-10-22 |
2011-01-04 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
|
US6689742B1
(en)
*
|
2000-02-25 |
2004-02-10 |
Chancellors, Masters And Scholars Of The University Of Oxford |
NY-ESO-1 peptide derivatives, and uses thereof
|
|
WO2001068853A2
(en)
*
|
2000-03-14 |
2001-09-20 |
The Johns Hopkins University School Of Medicine |
Immunogenic ovarian cancer genes
|
|
US6861234B1
(en)
|
2000-04-28 |
2005-03-01 |
Mannkind Corporation |
Method of epitope discovery
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
EP1752160A3
(en)
|
2001-04-06 |
2007-05-30 |
Mannkind Corporation |
Epitope sequences
|
|
EP1390387A4
(en)
*
|
2001-04-20 |
2004-12-08 |
Ludwig Inst Cancer Res |
TESTICLES CANCER ANTIGENS
|
|
US6794501B2
(en)
*
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
|
US7803382B2
(en)
*
|
2001-05-04 |
2010-09-28 |
Ludwig Institute For Cancer Research Ltd. |
Method for inducing immune response to NY-CO-58
|
|
MXPA04005382A
(es)
|
2001-11-07 |
2005-02-24 |
Mannkind Corp |
Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
|
|
MY147019A
(en)
*
|
2002-03-13 |
2012-10-15 |
Biogen Idec Inc |
Anti-alpha v beta 6 antibodies
|
|
EP1545610A4
(en)
*
|
2002-09-06 |
2006-11-08 |
Mannkind Corp |
EPITOPE SEQUENCES
|
|
US20080139464A1
(en)
*
|
2003-05-30 |
2008-06-12 |
Ludwig Institute Of Cancer Research |
Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
|
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
|
US20050118186A1
(en)
*
|
2003-06-17 |
2005-06-02 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in compositions for various types of cancers
|
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
WO2005114203A2
(en)
*
|
2004-05-20 |
2005-12-01 |
The Regents Of The University Of California |
Dominant b cell epitopes and methods of making and using thereof
|
|
US20060008468A1
(en)
*
|
2004-06-17 |
2006-01-12 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
US20060159689A1
(en)
*
|
2004-06-17 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
KR20070056042A
(ko)
*
|
2004-06-17 |
2007-05-31 |
맨카인드 코포레이션 |
에피토프 유사체
|
|
AU2005321898B2
(en)
|
2004-12-29 |
2012-07-19 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
|
WO2006071989A2
(en)
*
|
2004-12-29 |
2006-07-06 |
Mannkind Corporation |
Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
|
|
NZ587601A
(en)
|
2005-06-17 |
2012-05-25 |
Mannkind Corp |
Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
|
|
US7511118B2
(en)
*
|
2005-06-17 |
2009-03-31 |
Mannkind Corporation |
PSMA peptide analogues
|
|
EP2385059A3
(en)
|
2005-06-17 |
2012-02-15 |
Mannkind Corporation |
Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US8309096B2
(en)
*
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
US8236318B2
(en)
|
2007-11-07 |
2012-08-07 |
Celldex Therapeutics Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
WO2009114207A2
(en)
|
2008-03-14 |
2009-09-17 |
Sanofi Pasteur Biologics Co. |
Replication-defective flavivirus vaccines and vaccine vectors
|
|
BRPI1009873A2
(pt)
|
2009-03-17 |
2016-03-08 |
Glaxosmithkline Biolog Sa |
detecção aperfeiçoada de expressão gênica
|
|
GB0910046D0
(en)
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトｃｄ２７に結合する抗体およびその使用
|
|
LT2714071T
(lt)
|
2011-05-24 |
2019-10-10 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizuotos vakcinos nuo vėžio
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
US8490054B2
(en)
|
2011-09-23 |
2013-07-16 |
The United States Of America As Represented By The Secretary Of The Army |
Software and related software tracking during software modification
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
AU2013351542B2
(en)
|
2012-11-28 |
2018-08-09 |
BioNTech SE |
Individualized vaccines for cancer
|
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
EP3194970B1
(en)
|
2014-09-10 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Immunogenic mutant peptide screening platform
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
|
NL2018803B1
(en)
|
2017-04-27 |
2018-11-05 |
Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc |
Adjuvant compounds
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
AU2020402581A1
(en)
|
2019-12-11 |
2022-06-23 |
Molecular Partners Ag |
Designed ankyrin repeat domains with altered surface residues
|
|
KR20260071132A
(ko)
*
|
2024-11-11 |
2026-05-19 |
연세대학교 산학협력단 |
자폐증 개선 또는 치료를 위한 뇌내 조절 t 세포 활성화 방법
|